Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Biological effects of platelet-derived growth factor receptor alpha lockade in uterine cancer

ABSTRACT: Platelet-derived growth factor receptor alpha (PDGFRα) expression is frequently observed in many kinds of cancer and is a candidate for therapeutic targeting. Here, we evaluated the biological significance of PDGFRα and PDGFRα blockade (using a fully humanized monoclonal antibody, 3G3) in uterine cancer. PDGFRα was expressed in uterine cancer cells, and its blockade with 3G3 resulted in inhibition of PDGFRα phosphorylation and of downstream signaling molecules, AKT and MAPK. Cell viability and invasive potential of uterine cancer cells were also inhibited by treatment of 3G3. Moreover, greater therapeutic effects were observed for 3G3 in combination with chemotherapy than for either drug alone in orthotopic mouse models of uterine cancer. These findings identify PDGFRα as an attractive therapeutic target for uterine cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE55483 | GEO | 2014/06/04

SECONDARY ACCESSION(S): PRJNA239753

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Biological effects of platelet-derived growth factor receptor alpha lockade in uterine cancer

Project description:Platelet-derived growth factor receptor alpha (PDGFRα) expression is frequently observed in many kinds of cancer and is a candidate for therapeutic targeting. Here, we evaluated the biological significance of PDGFRα and PDGFRα blockade (using a fully humanized monoclonal antibody, 3G3) in uterine cancer. PDGFRα was expressed in uterine cancer cells, and its blockade with 3G3 resulted in inhibition of PDGFRα phosphorylation and of downstream signaling molecules, AKT and MAPK. Cell viability and invasive potential of uterine cancer cells were also inhibited by treatment of 3G3. Moreover, greater therapeutic effects were observed for 3G3 in combination with chemotherapy than for either drug alone in orthotopic mouse models of uterine cancer. These findings identify PDGFRα as an attractive therapeutic target for uterine cancer. Two groups of samples are included: 1.Hec-1A 2.Rl-95-2. Gene expression profiles of Hec-1A cells were compared to that of RL95-2 cells.

2014-06-04 | E-GEOD-55483 | biostudies-arrayexpress

Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in Uterine Fibroids and Breast Cancer (ChIP-Seq)

Project description:Analysis of genes regulated by RU486 (an progesterone antagonist) in human breast cancer T47D cells and human uterine leiomyoma smooth muscle cells. The hypothesis is that RU486 inhibits tumor growth by inactivating the transcription of multiple genes which trigger critical signaling pathways to induce tumorigenesis in both breast caner and uterine leomyoma. Tissue-specific and common patterns of gene regulation may determine the therapeutic effects of antiprogestins in uterine leiomyoma and breast cancer. We applied ChIP-seq to identify PR-interaction sites in T47D breast cancer cells and primary uterine leiomyoma cells treated with RU486.

2012-09-11 | E-GEOD-40724 | biostudies-arrayexpress

Platelet-derived growth factor receptor signaling is required for postnatal tendon growth

Project description:Platelet-derived growth factor receptor (PDGFR) signaling plays an important role in the embryonic formation of many different tissues. There is a family of PDGF isoforms which signal through the PDGF receptors α (PDGFRα) and β (PDGFRβ). PDGF regulates many key cellular processes of mesenchymal cell function including proliferation, differentiation, migration and extracellular matrix (ECM) synthesis. While PDGF has been used to enhance flexor tendon healing in vivo, its role in postnatal tendon growth has remained largely unexplored. To determine the importance of PDGFR signaling in postnatal tendon growth, we performed pharmacological blockade of PDGFRα and PDGFRβ, and then induced tendon growth via mechanical overload using the hindlimb synergist ablation model. Our hypothesis was that inhibition of PDGFR signaling will restrict normal growth of tendon tissue in response to mechanical loading.

2017-03-08 | GSE95794 | GEO

Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in Uterine Fibroids and Breast Cancer

Project description:Analysis of genes regulated by RU486 (an progesterone antagonist) in human breast cancer T47D cells and human uterine leiomyoma smooth muscle cells. The hypothesis is that RU486 inhibits tumor growth by inactivating the transcription of multiple genes which trigger critical signaling pathways to induce tumorigenesis in both breast caner and uterine leomyoma. Tissue-specific and common patterns of gene regulation may determine the therapeutic effects of antiprogestins in uterine leiomyoma and breast cancer. Total RNA isolated from T47D cells subjected to RU486 treatment for 6 hours compared to vehicle (ethanol) treated cells. Total RNA isolated from uterine leiomyoma cells subjected to RU486 treatment for 6 hours compared to vehicle (ethanol) treated cells.

2011-07-22 | E-GEOD-30871 | biostudies-arrayexpress

Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in Uterine Fibroids and Breast Cancer (Expression BeadChip)

Project description:Analysis of genes regulated by RU486 (an progesterone antagonist) in human breast cancer T47D cells and human uterine leiomyoma smooth muscle cells. The hypothesis is that RU486 inhibits tumor growth by inactivating the transcription of multiple genes which trigger critical signaling pathways to induce tumorigenesis in both breast caner and uterine leomyoma. Tissue-specific and common patterns of gene regulation may determine the therapeutic effects of antiprogestins in uterine leiomyoma and breast cancer. Keywords: Expression profiling by array Total RNA isolated from T47D cells subjected to RU486 treatment for 6 hours compared to vehicle (ethanol) treated cells. Total RNA isolated from uterine leiomyoma cells subjected to RU486 treatment for 6 hours compared to vehicle (ethanol) treated cells.

2012-09-11 | E-GEOD-40725 | biostudies-arrayexpress

Tamoxifen Activates PI3Kinase Signaling in Uterine Cancer and Substitutes for the lack of PIK3CA Mutations

Project description:Tamoxifen treatment in breast cancer patients increases their risk of developing uterine cancer that is more likely of poor prognosis. However, the exact mechanism leading to this increased and the worse outcomeendometrial cancer risk following tamoxifen exposure are still unknown, and effective preventive strategies are lacking. To address this question, we performed whole-exome sequencing of 21 (discovery cohort) and digital droplet PCR for 40 (validation cohort ) tamoxifen-associated uterine cancers. We identified genomic features that have been previously reported for uterine cancer, including recurrent mutations in PTEN, KRAS, TP53 and ARIDA1 and copy number alterations in the RTK and PI3K pathway. However, we also found that tamoxifen-associated uterine cancers have a substantially low frequency of PIK3CA and PIK3R1 mutations, the most prevalent mutations in non-tamoxifen-associated uterine cancers. Moreover, overall survival is significantly worse in uterine tumors without PIK3CA mutations, which could explain the observed poor prognosis in tamoxifen-associated uterine cancers . We also performed in vivo studies of normal uterine tissue and show that tamoxifen activates the PI3Kinase pathway and increases proliferation that in turn is abrogated by the PI3Kinase inhibitor, alpelisib. Together, this study uncovers the unique molecular profile of tamoxifen-associated uterine cancer and , offers mechanistic insights in the observed increase in endometrial cancer risk following tamoxifen treatment and a potential preventive approach. Moreover, we here describe for the first time a new general principle that a drug, as a side effect, can activate a pathway which would otherwise only be activated if a somatic mutation would have occurred thereby mimicking the effect of a driver mutation for cancer.

2022-07-07 | GSE179647 | GEO

Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in Uterine Fibroids and Breast Cancer (ChIP-Seq)

2012-09-11 | GSE40724 | GEO

Genome-Wide Progesterone Receptor Binding: Cell Type-Specific and Shared Mechanisms in Uterine Fibroids and Breast Cancer (Expression BeadChip)

2012-09-11 | GSE40725 | GEO

Towards Optimization of Precision Oncology in Metastatic Uterine Tumors

Project description:Precision oncology and its diagnostic tools are essential for developing personalized cancer treatments. The purpose of this study was to integrate data on the digital patterns of reticulin fiber scaffolding and the immune cell infiltrate, transcriptomic and epigenetic profiles in aggressive uterine adenocarcinoma (uADC), uterine leiomyosarcoma (uLMS) and their respective lung metastases (LM-uADC and LM-uLMS), with the aim of obtaining key tumor microenvironment (TME) biomarkers that can help improve metastatic prediction and shed light on potential therapeutic targets.

2022-12-16 | GSE216313 | GEO

Uterine microbiota

Project description:Uterine microbiota Metagenome

| PRJNA480713 | ENA